A Single-arm, Open, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of KC1036 in the Patients with Advanced Recurrent or Metastatic Thymic Tumors
Overview
- Phase
- Phase 2
- Intervention
- KC1036
- Conditions
- Thymic Tumors
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
- Enrollment
- 30
- Locations
- 2
- Primary Endpoint
- Objective Response Rate (ORR)
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
This is a single arm，open-label, multicentric, phase II study to evaluate the efficacy and safety of KC1036 in patients with advanced recurrent or metastatic thymoma or thymic carcinoma.
Detailed Description
Thymus tumor is a relatively rare type of thoracic tumor. Patients with thymus tumor who have failed to receive first-line chemotherapy lack of effective therapeutic drugs and clinical need is urgent. Previous phase I study showed that KC1036 has a good therapeutic effect in patients with advanced thymic tumors, and KC1036 is safe and well tolerated in patients with advanced tumors. This study further explored the efficacy and safety of KC1036 in patients with advanced thymic tumors. Patients will receive continuous treatment with oral KC1036 60 mg once daily. Each cycle will be considered as 21 days of treatment; safety was assessed every 21 days. Tumor assessement will be done every two cycles. Treatment should be administered until documented disease progression, unacceptable toxicity, or patient refusal.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with thymoma or thymic carcinoma confirmed by cytologically or histologically (WHO Classification of Thoracic Tumors 5th ed), including all pathological subtypes;
- •Patients with advanced recurrent, unresectable and/or metastatic thymic tumor as defined by the Masaoka-Koga stage;
- •Subsequent relapse of disease following first-line systemic chemotherapy;
- •Patients with at least one measurable lesion as defined by RECIST V1.1; Measurable lesions located within the radiation field of previous radiotherapy or after local treatment can also be selected as target lesions if progression is confirmed.
- •Eastern Cooperative Oncology Group performance status score of 0 or 1;
- •Life expectancy \> 12 weeks;
- •Adequate organ and marrow function;
- •Patients should participate in the study voluntarily and sign informed consent.
Exclusion Criteria
- •Patients with thymus neuroendocrine tumors;
- •Any patient who is known to have central nervous system (CNS) metastasis or imaging shows a risk of CNS metastasis;
- •Previous (within the last 5 years) or current malignancies at other sites;
- •Gastrointestinal abnormalities;
- •Cardiovascular and cerebrovascular diseases;
- •Patients who have previous treatment with small molecule VEGFR-TKI (except patients whose treatment cycle is less than 2 weeks due to intolerance or other reasons); Patients who have previous treatment with PD-1 / PD-L1 antibody combined with small molecule VEGFR-TKI;
- •Involved in other clinical trials within 4 weeks before enrollment; Prior anti-tumor therapies with chemotherapy, cytotherapy, immunotherapy, operation (Interventional therapy excepted) within 4 weeks 4 weeks before enrollment; Prior radiotherapy (palliative radiotherapy excepted) within 2 weeks; Prior small-molecule targeted therapy within 2 weeks or 5 half-lives.
- •Presence of unresolved toxicities from prior anti-tumor therapy, defined as having not resolved to NCI CTCAE V5.0 grade 0 or 1 with the exception of alopecia;
- •Skin wound, surgical site, wound site, mucous membrane severe ulcer or fracture comfirmed as having not recovered;
- •Uncontrolled mass pleural effusion, ascites, and pericardial effusion;
Arms & Interventions
KC1036
60mg QD
Intervention: KC1036
Outcomes
Primary Outcomes
Objective Response Rate (ORR)
Time Frame: approximately 2 year
Overall response rate (ORR) was defined as the percentage of participants with a best overall complete response (CR) or partial response (PR) per RECIST 1.1.
Secondary Outcomes
- Disease Control Rate (DCR)(approximately 2 year)
- Progression-free survival (PFS)(approximately 2 year)
- Duration of Response (DOR)(approximately 2 year.)
- Adverse events (AEs)(approximately of 2 year)